Ensysce Biosciences Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ENSC$0.36+10.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Stockholders’ Equity (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional | ||||||
| Number of Shares | Amount | Paid-In Capital | Accumulated Deficit | Noncontrolling interests | Total | |
| Balance on June 30, 2023 | 2,669,792 | $267 | $119,481,957 | $(115,363,208) | $(326,209) | $3,792,807 |
| Settlement of restricted stock units | 314 | - | - | - | - | - |
| Issuance of common stock upon exercise of warrants | 193,898 | 20 | (20) | - | - | - |
| Stock-based compensation | - | - | 55,674 | - | - | 55,674 |
| Net loss | - | - | - | (2,689,571) | (1,235) | (2,690,806) |
| Balance on September 30, 2023 | 2,864,004 | $287 | $119,537,611 | $(118,052,779) | $(327,444) | $1,157,675 |
| Balance on June 30, 2024 | 8,151,172 | $815 | $128,448,699 | $(126,641,646) | $(328,483) | $1,479,385 |
| Public offering | 3,553,194 | 355 | 1,669,646 | - | - | 1,670,001 |
| Issuance of common stock upon warrant inducement | 2,166,144 | 217 | 3,385,430 | - | - | 3,385,647 |
| Transaction costs associated with public offering and warrant inducement | - | - | (637,894) | - | - | (637,894) |
| Stock-based compensation | - | - | 20,819 | - | - | 20,819 |
| Net income | - | - | 661,769 | - | 661,769 | |
| Balance on September 30, 2024 | 13,870,510 | $1,387 | $132,886,700 | $(125,979,877) | $(328,483) | $6,579,727 |
| Balance on December 31, 2022 | 534,490 | $53 | $107,216,566 | $(110,931,063) | $(315,208) | $(4,029,652) |
| Settlement of restricted stock units | 938 | - | - | - | - | - |
| Settlement of commitment fee | 44,444 | 4 | 399,996 | - | - | 400,000 |
| Conversion of convertible notes | 408,580 | 41 | 3,056,851 | - | - | 3,056,892 |
| Public offerings, net | 1,381,619 | 139 | 9,049,865 | - | - | 9,050,004 |
| Transaction costs associated with public offerings | - | - | (447,879) | - | - | (447,879) |
| Issuance of common stock upon exercise of warrants | 494,795 | 50 | (50) | - | - | - |
| Stock-based compensation | - | - | 250,224 | - | 250,224 | |
| Reverse split fractional shares | (862) | - | - | - | - | - |
| Deemed dividend related to warrants down round provision | - | - | 12,038 | (12,038) | - | - |
| Net loss | - | - | - | (7,109,678) | (12,236) | (7,121,914) |
| Balance on September 30, 2023 | 2,864,004 | $287 | $119,537,611 | $(118,052,779) | $(327,444) | $1,157,675 |
| Balance on December 31, 2023 | 3,146,076 | $315 | $121,233,901 | $(121,557,074) | $(328,409) | $(651,267) |
| Settlement of restricted stock units | 63 | - | - | - | - | - |
| Conversion of convertible notes | 745,521 | 75 | 1,168,525 | - | - | 1,168,600 |
| Public offering | 3,553,194 | 355 | 1,669,646 | - | - | 1,670,001 |
| Issuance of common stock upon exercise of warrants | 1,323,904 | 132 | 2,075,087 | - | - | 2,075,219 |
| Issuance of common stock upon warrant inducements | 5,101,752 | 510 | 8,103,433 | - | - | 8,103,943 |
| Transaction costs associated with public offering and warrant inducements | - | - | (1,444,756) | - | - | (1,444,756) |
| Stock-based compensation | - | - | 80,574 | - | - | 80,574 |
| Deemed dividend related to warrants down round provision | - | - | 290 | (290) | - | - |
| Net loss | - | - | - | (4,422,513) | (74) | (4,422,587) |
| Balance on September 30, 2024 | 13,870,510 | $1,387 | $132,886,700 | $(125,979,877) | $(328,483) | $6,579,727 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.